Updates are available Correction dated 2024-04-22

Article History

Received: 25 February 2022

Accepted: 2 December 2022

First Online: 30 March 2023

Change Date: 22 April 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41591-024-02998-5

Competing interests

: I.C.G.O. has consulted for Bristol Myers Squibb, Array, Novartis and Sintetica; and has been the PI of research funding to MD Anderson by Bristol Myers Squibb, Merck and Pfizer. I.C.G.O. is also funded by the MD Anderson Cancer Melanoma Moonshot and P50CA221703. S.D.F. has previously received research funding from Codiak, and has also been funded by MD Anderson Cancer Center Melanoma Moon Shot Program and P50CA221703. R.B. Jr, A.P.F., I.J., T.D.H., M.R., J.R., M.I., T.D., C.L., N.J., T.R., S.P., S.D., L.H. and R.L. have no competing interests to declare. R.N.A. has received research funding from Bristol Myers Squibb, Novartis, Iovance, Obsidian and Merck. M.K.W. has participated in advisory boards for the following entities: Merck, Pfizer, Bristol Myers Squibb, Regeneron, EMD Serono, Exicure and Castle Biosciences. A.D. has consulted for Bristol Myers Squibb and has been PI of research funding to MD Anderson by Bristol Myers Squibb. C.Y. has consulted for Grey Wolf Therapeutics, Immatics Biotechnologies, RootPath, T-Cypher Bio, GenomeFrontier Therapeutics and Achelois Oncology. S.P.P. has received research funding from Bristol Myers Squibb, Foghorn Therapeutics, InxMed, Novartis, Provectus, Reata Pharmaceuticals and TriSalus Life Sciences; has consulted for Advance Knowledge in Healthcare; and serves on advisory boards for Cardinal Health, Castle Biosciences and TriSalus Life Sciences. J.L.M. has consulted for Merck and has received honorariums from Bristol Myers Squibb and Roche. G.M.F., I.E.M., B.J.O., S.T., M.D. and N.G.-T. have no competing interests to declare. J.A.W. is an inventor on patent WO2020106983A1 submitted by the Board of Regents, The University of Texas System and Institute Gustav Roussy that covers methods and compositions for treating cancer and for predicting a subject’s response to combination checkpoint inhibitor therapy. J.A.W. is inventor on a US patent application (PCT/US17/53.717) submitted by the University of Texas MD Anderson Cancer Center that covers methods to enhance ICB responses by modulating the microbiome. J.A.W. is inventor on patent WO2020150429A1 submitted by the Board of Regents, The University of Texas System, that covers methods and compositions for treating immune checkpoint inhibitor-associated colitis in a subject through the administration of fecal matter from a healthy donor to the subject. J.A.W. reports compensation for speaker’s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune and Bristol Myers Squibb; and serves as a consultant and/or advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Merck, Biothera Pharmaceuticals, Microbiome DX and Micronoma. J.A.W. also receives research support from GlaxoSmithKline, Roche/Genentech, Bristol Myers Squibb and Novartis. E.M.B. has no competing interest to declare. H.A.T. has been a consultant to Bristol Myers Squibb, Genentech, Novartis, Merck, Boxer Capital, Karyopharm, Iovance, Eisai Jazz Pharmaceuticals and Medicenna; and has been the PI of research funding to MD Anderson by Bristol Myers Squibb, Novartis, Merck, Genentech, GlaxoSmithKline, EMD Serono, Eisai, Dragonfly Therapeutics and RAPT Therapeutics. M.A.D. has been a consultant to Roche/Genentech, Array, Pfizer, Novartis, Bristol Myers Squibb, GlaxoSmithKline, Sanofi-Aventis, Vaccinex, Apexigen, Eisai and ABM Therapeutics; and has been the PI of research grants to MD Anderson by Roche/Genentech, GlaxoSmithKline, Sanofi-Aventis, Merck, Myriad and Oncothyreon; and is supported by the Dr Miriam and Sheldon G. Adelson Medical Research Foundation, the AIM at Melanoma Foundation, the National Institutes of Health/National Cancer Institute 1 P50 -02, the American Cancer Society and the Melanoma Research Alliance, Cancer Fighters of Houston, the Anne and John Mendelsohn Chair for Cancer Research and philanthropic contributions to the MD Anderson Cancer Center Melanoma Moon Shot Program.